What is ABIOMED?
ABIOMED is dedicated to developing and manufacturing advanced cardiovascular products, with a core focus on technologies that support or replace the natural pumping mechanism of the heart. Headquartered in Danvers, Massachusetts, the company has established itself as a leader in the medical device industry through its commitment to innovation and patient outcomes. Its product portfolio is engineered to address critical cardiac conditions, offering solutions that range from temporary support to long-term assistance for patients with severe heart failure.
How much funding has ABIOMED raised?
ABIOMED has raised a total of $42.1M across 1 funding round:
Stock Offering
$42.1M
Stock Issuance/Offering (2008): $42.1M, investors not publicly disclosed
What's next for ABIOMED?
The substantial enterprise-level funding and recent strategic investment signal a pivotal phase for ABIOMED. This capital infusion is expected to accelerate the company's research and development initiatives, potentially leading to the expansion of its product pipeline and the enhancement of existing technologies. Furthermore, the financing will likely support broader market penetration and global expansion efforts, solidifying ABIOMED's position as a key innovator in the cardiovascular medical device sector. The company's trajectory suggests a continued focus on addressing unmet clinical needs in cardiology.
See full ABIOMED company page
